Cargando…

Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations

PURPOSE: Although epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) usually show sensitivity to first-generation EGFR-tyrosine kinase inhibitors (TKIs), most patients relapse because of drug resistance. Heat shock protein 27 (HSP27) has been reported...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Seul-Ki, Kim, Minsuh, Lee, Haeseung, Kwon, Youngjoo, Cha, Hyuk-Jin, Jang, Se Jin, Na, Younghwa, Lee, Yun-Sil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579113/ https://www.ncbi.nlm.nih.gov/pubmed/35931945 http://dx.doi.org/10.1007/s13402-022-00696-3

Ejemplares similares

Drug-Like Small Molecule HSP27 Functional Inhibitor Sensitizes Lung Cancer Cells to Gefitinib or Cisplatin by Inducing Altered Cross-Linked Hsp27 Dimers
por: Yoo, Hawon, et al.
Publicado: (2021)

Sensitization of lung cancer cells by altered dimerization of HSP27
por: Choi, Byeol, et al.
Publicado: (2017)

Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules
por: Kim, Jee Hye, et al.
Publicado: (2016)

Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance
por: Hwang, Soo-Yeon, et al.
Publicado: (2020)

The miR-15b-Smurf2-HSP27 axis promotes pulmonary fibrosis
por: Jeon, Seulgi, et al.
Publicado: (2023)

HSP27 inhibitor attenuates radiation-induced pulmonary inflammation
por: Kim, Jee-Youn, et al.
Publicado: (2018)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2014)

Drug like HSP27 cross linkers with chromenone structure ameliorates pulmonary fibrosis
por: Yoo, Young Jo, et al.
Publicado: (2023)

Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
por: Deng, Qin-fang, et al.
Publicado: (2020)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
por: Bokobza, Sivan M., et al.
Publicado: (2014)

Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
por: Wang, Yue-qin, et al.
Publicado: (2020)

3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases
por: Lee, Jin-Young, et al.
Publicado: (2023)

Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET
por: Lee, Jin-Young, et al.
Publicado: (2023)

Heat‐shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF
por: Konda, John D., et al.
Publicado: (2017)

Expressions of HSP70 and HSP27 in Hepatocellular Carcinoma
por: Joo, Mee, et al.
Publicado: (2005)

The HSP90/Akt pathway may mediate artemether‐induced apoptosis of Cal27 cells
por: Wu, Jianhua, et al.
Publicado: (2019)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Liu, Pengfei, et al.
Publicado: (2019)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
por: Cho, Jung Hee, et al.
Publicado: (2022)

HSP27 and HSP70 expression in squamous cell carcinoma: An immunohistochemical study
por: Deyhimi, Parviz, et al.
Publicado: (2012)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer
por: Ren, Hui, et al.
Publicado: (2019)

Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk
por: Peng, Mei, et al.
Publicado: (2016)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway
por: Jin, Huang, et al.
Publicado: (2019)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
por: Britain, Colleen M., et al.
Publicado: (2018)

TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells
por: Choi, Jeong‐Yun, et al.
Publicado: (2020)

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer
por: Bae, Gab-Yong, et al.
Publicado: (2013)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
por: Xiao, Fengqi, et al.
Publicado: (2020)

Hsp27 and Hsp70 Expression in Esophageal Squamous
por: Luz, Caio Cesar Floriano, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4is00gbf3236ue6nb1963th2o5